Oregon · G0103

Prostate Cancer Screening; Prostate Specific Antigen Test (psa) in Oregon

Oregon Medicare Avg
$18.87
0% below national avg
National Medicare Avg
$18.87
All states combined
Billed Charge (OR)
$54.52
What providers submit
Est. Commercial (OR)
$43.39
National avg: $42.27
Est. Cash / Self-Pay (OR)
$29.14
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

14.5K
Services in OR
238
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in Oregon

Provider Medicare Services
Interpath Laboratory, Inc. $18.87 6.9K
Legacy Laboratory Services, Llc $18.91 1.8K
Laboratory Corporation Of America $18.92 1.1K
North Bend Medical Center Inc $18.73 1.0K

Oregon Pricing in Context

In Oregon, CPT code G0103 (Prostate Cancer Screening; Prostate Specific Antigen Test (psa)) carries an average Medicare payment of $18.87 — 0% below the national benchmark of $18.87. 238 providers across the state submitted claims for this procedure in 2023, performing 14.5K total services. Individual payments in OR ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in Oregon is $54.52, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because Oregon sits below the national Medicare average, commercial rates in the state may also run lower than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Preventive Screening procedures, the estimated commercial insurance price in Oregon lands near $43.39, with self-pay cash prices typically around $29.14. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Prostate Cancer Screening; Prostate Specific Antigen Test (psa) cost in Oregon?

The average Medicare payment for Prostate Cancer Screening; Prostate Specific Antigen Test (psa) in Oregon is $18.87, which is 0% below the national average of $18.87. Providers in OR typically bill $54.52 for this procedure.

What does Prostate Cancer Screening; Prostate Specific Antigen Test (psa) cost with insurance in Oregon?

With commercial insurance in Oregon, Prostate Cancer Screening; Prostate Specific Antigen Test (psa) costs an estimated $43.39. Without insurance, the estimated cash price is $29.14. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Prostate Cancer Screening; Prostate Specific Antigen Test (psa) in Oregon?

238 providers in Oregon billed Medicare for Prostate Cancer Screening; Prostate Specific Antigen Test (psa) in 2023, performing 14.5K total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Prostate Cancer Screening; Prostate Specific Antigen Test (psa) cheaper in Oregon than the national average?

Yes — Prostate Cancer Screening; Prostate Specific Antigen Test (psa) costs 0% below the national average in Oregon. The state average Medicare payment is $18.87 compared to $18.87 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial